Patient characteristics
| . | Total (n = 323) . | MYC-WT DLBCL (n = 245) . | MYC-SH DLBCL (n = 24) . | DH/TH (n = 54) . |
|---|---|---|---|---|
| Gender | ||||
| Male | 185 (57) | 131 (53) | 15 (63) | 39 (72) |
| Female | 138 (43) | 114 (47) | 9 (38) | 15 (28) |
| Age (interquartile range), y | 63 (53-71) | 64 (54-71) | 57 (45-66) | 63 (55-71) |
| Ann Arbor stage | ||||
| I | 23 (7) | 20 (8) | 2 (8) | 1 (2) |
| II | 54 (17) | 44 (18) | 5 (21) | 5 (9) |
| III | 73 (23) | 62 (25) | 3 (13) | 8 (15) |
| IV | 173 (54) | 119 (49) | 14 (58) | 40 (74) |
| Lactate dehydrogenase | ||||
| Normal | 124 (38) | 103 (42) | 9 (38) | 12 (22) |
| >Normal | 199 (62) | 142 (58) | 15 (63) | 42 (78) |
| Extranodal involvement | ||||
| 0-1 | 204 (63) | 166 (68) | 16 (67) | 22 (41) |
| >1 | 119 (37) | 79 (32) | 8 (33) | 32 (59) |
| World Health Organization performance status | ||||
| 0 | 186 (58) | 142 (58) | 15 (63) | 29 (54) |
| 1 | 100 (31) | 74 (30) | 8 (33) | 18 (33) |
| 2 | 33 (10) | 26 (11) | 1 (4) | 6 (11) |
| 3 | 4 (1) | 3 (1) | 1 (2) | |
| IPI | ||||
| Low | 83 (26) | 68 (28) | 8 (33) | 7 (13) |
| Low-intermediate | 65 (20) | 51 (21) | 4 (17) | 10 (19) |
| High-intermediate | 104 (32) | 75 (31) | 8 (33) | 21 (39) |
| High | 71 (22) | 51 (21) | 4 (17) | 16 (30) |
| Treatment | ||||
| 6 × R-CHOP | 99 (31) | 94 (38) | 1 (4) | 4 (7) |
| 8 × R-CHOP | 29 (9) | 24 (10) | 2 (8) | 3 (6) |
| 6 × R-CHOP + 2 × R | 71 (22) | 67 (27) | 2 (8) | 2 (4) |
| 6 × RR-CHOP | 44 (14) | 41 (17) | 2 (8) | 1 (2) |
| 8 × RR-CHOP | 22 (7) | 18 (7) | 1 (4) | 3 (6) |
| Burkitt protocol | 4 (1) | 1 (1) | 2 (8) | 1 (2) |
| 6 × R2-CHOP + 2 × R | 54 (17) | 14 (59) | 40 (74) |
| . | Total (n = 323) . | MYC-WT DLBCL (n = 245) . | MYC-SH DLBCL (n = 24) . | DH/TH (n = 54) . |
|---|---|---|---|---|
| Gender | ||||
| Male | 185 (57) | 131 (53) | 15 (63) | 39 (72) |
| Female | 138 (43) | 114 (47) | 9 (38) | 15 (28) |
| Age (interquartile range), y | 63 (53-71) | 64 (54-71) | 57 (45-66) | 63 (55-71) |
| Ann Arbor stage | ||||
| I | 23 (7) | 20 (8) | 2 (8) | 1 (2) |
| II | 54 (17) | 44 (18) | 5 (21) | 5 (9) |
| III | 73 (23) | 62 (25) | 3 (13) | 8 (15) |
| IV | 173 (54) | 119 (49) | 14 (58) | 40 (74) |
| Lactate dehydrogenase | ||||
| Normal | 124 (38) | 103 (42) | 9 (38) | 12 (22) |
| >Normal | 199 (62) | 142 (58) | 15 (63) | 42 (78) |
| Extranodal involvement | ||||
| 0-1 | 204 (63) | 166 (68) | 16 (67) | 22 (41) |
| >1 | 119 (37) | 79 (32) | 8 (33) | 32 (59) |
| World Health Organization performance status | ||||
| 0 | 186 (58) | 142 (58) | 15 (63) | 29 (54) |
| 1 | 100 (31) | 74 (30) | 8 (33) | 18 (33) |
| 2 | 33 (10) | 26 (11) | 1 (4) | 6 (11) |
| 3 | 4 (1) | 3 (1) | 1 (2) | |
| IPI | ||||
| Low | 83 (26) | 68 (28) | 8 (33) | 7 (13) |
| Low-intermediate | 65 (20) | 51 (21) | 4 (17) | 10 (19) |
| High-intermediate | 104 (32) | 75 (31) | 8 (33) | 21 (39) |
| High | 71 (22) | 51 (21) | 4 (17) | 16 (30) |
| Treatment | ||||
| 6 × R-CHOP | 99 (31) | 94 (38) | 1 (4) | 4 (7) |
| 8 × R-CHOP | 29 (9) | 24 (10) | 2 (8) | 3 (6) |
| 6 × R-CHOP + 2 × R | 71 (22) | 67 (27) | 2 (8) | 2 (4) |
| 6 × RR-CHOP | 44 (14) | 41 (17) | 2 (8) | 1 (2) |
| 8 × RR-CHOP | 22 (7) | 18 (7) | 1 (4) | 3 (6) |
| Burkitt protocol | 4 (1) | 1 (1) | 2 (8) | 1 (2) |
| 6 × R2-CHOP + 2 × R | 54 (17) | 14 (59) | 40 (74) |
All data are presented as number of patients (%), unless indicated otherwise.